Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeNo recent work listed

Mengyi Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9348-6876; OpenAlex author ID A5101531771. Sources: OpenAlex.

Their work

Papers
14 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2015: 3 papers · 2016: 4 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper

Papers 14

  1. GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.968610↗
  2. The promoting effects of hsa_circ_0050102 in pancreatic cancer and the molecular mechanism by targeting miR-1182/NPSR1. Co-author DOI 10.1093/carcin/bgaa130↗
  3. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.774435↗
  4. Up-regulation of CDHR5 expression promotes malignant phenotype of pancreatic ductal adenocarcinoma. First author DOI 10.1111/jcmm.15856↗
  5. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. Co-author DOI 10.7150/jca.40517↗
  6. Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by up-regulation of CD59. Co-author DOI 10.1038/s41419-019-2065-4↗
  7. Interleukin-27 inhibits malignant behaviors of pancreatic cancer cells by targeting M2 polarized tumor associated macrophages. First author DOI 10.1016/j.cyto.2015.12.003↗
  8. Immunoglobulin G4 (IgG4)-positive plasma cell infiltration is associated with the clinicopathologic traits and prognosis of pancreatic cancer after curative re… Co-author DOI 10.1007/s00262-016-1853-2↗
  9. G-protein-coupled receptor kinase 2 in pancreatic cancer: clinicopathologic and prognostic significance. First author DOI 10.1016/j.humpath.2016.06.012↗
  10. Prognostic Impact of Cell Division Cycle Associated 2 Expression on Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/s1001-9294(16)30043-8↗
  11. Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by … Co-author DOI 10.1186/s13046-016-0304-4↗
  12. Elevated GRP78 expression is associated with poor prognosis in patients with pancreatic cancer. First author DOI 10.1038/srep16067↗
  13. Changes in the Expression of Glucose-regulated Protein 78 in the Occurrence and Progression of Pancreatic Cancer in Mouse Models. Co-author DOI 10.3881/j.issn.1000-503x.2015.03.002↗
  14. HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer. Co-author PMID 26692947↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Quan Liao · 13 shared papers, 2015–2022 · strength 1.22
  2. Qiaofei Liu · 9 shared papers, 2015–2022 · strength 0.91
  3. Junyi Gao · 4 shared papers, 2020–2022 · strength 0.59
  4. Yupei Zhao · 6 shared papers, 2015–2020 · strength 0.47
  5. Zheyu Niu · 7 shared papers, 2015–2017 · strength 0.43
  6. Ming Cui · 3 shared papers, 2020–2022 · strength 0.42
  7. Lei You · 4 shared papers, 2015–2021 · strength 0.39
  8. Tong Li · 3 shared papers, 2020–2021 · strength 0.38
  9. Li Zhou · 5 shared papers, 2015–2017 · strength 0.32
  10. Yalu Zhang · 2 shared papers, 2021–2022 · strength 0.31
  11. Lutian Yao · 5 shared papers, 2015–2017 · strength 0.30
  12. Surong Hua · 2 shared papers, 2021 · strength 0.29
  13. Yu-Pei Zhao · 4 shared papers, 2015–2016 · strength 0.24
  14. Ronghua Zhang · 2 shared papers, 2019–2020 · strength 0.21
  15. Junya Peng · 2 shared papers, 2019–2020 · strength 0.21
  16. Sen Yang · 1 shared paper, 2022 · strength 0.16
  17. Xianlin Han · 1 shared paper, 2021 · strength 0.14
  18. Boju Pan · 2 shared papers, 2016 · strength 0.12
  19. Zhiyong Liang · 2 shared papers, 2015–2016 · strength 0.11
  20. Xiang Zhang · 1 shared paper, 2020 · strength 0.11
  21. Jingkai Liu · 1 shared paper, 2020 · strength 0.11
  22. Quan Liao · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.